Targeting H3N2 influenza virus RNA dependent RNA polymerase dependent inhibitory activity by principal components from latex of Calotropis gigantean
Vol 6, Issue 2, 2023
VIEWS - 139 (Abstract) 92 (PDF)
Abstract
The H3N2 influenza virus is spiking dramatically, which is a major concern worldwide and in India. The multifunctional hetero-trimer influenza virus RNA-dependent RNA polymerase (RdRP) is involved in the generation of viral mRNA and is crucial for viral infectivity, which is directly related to the virus’s ability to survive. The goal of the current work was to use molecular docking to determine how the RdRP protein might be affected by powerful bioactive chemicals found in Calotropis gigantia latex. By applying CB-dock 2 analysis and 2D interactions, an in-silico docking study was conducted using a GC-FID (gas chromatography with flame-ionization detection) based composition profile. Tocospiro A (15%), Amyrin (7%), and Gombasterol A were found by GC-FID to be the main phytocompounds in the latex of Calotropis gigantia. The docking result showed that ligands were effectively bound to RdRP. According to interaction studies, RdRP/ligand complexes create hydrogen bonds, van der Waals forces, pi-alkyl bonds, alkyl bonds, and pi-Sigma bonds. Therefore, it was suggested that Calotropis gigantia latex may represent a possible herbal remedy to attenuate H3N2 infections based on the above findings of the fragrance profile and docking.
Keywords
Full Text:
PDFReferences
1. Leung Y, To M, Lam T, et al. Epidemiology of human influenza A(H7N9) infection in Hong Kong. Journal of Microbiology, Immunology and Infection 2017; 50(2): 183–188. doi: 10.1016/j.jmii.2015.06.004
2. Ali G S, Ozdemir B, Selamoglu Z. A review of severe acute respiratory syndrome coronavirus 2 and pathological disorders in patients. Journal of Pharmaceutical Care 2021; 9(3): 141–147. doi: 10.18502/jpc.v9i3.7373
3. Seladi-Schulman J. H3N2 flu: What you should know. Available online: https://www.healthline.com/health/h3n2 (accessed on 8 November 2023).
4. Jin Z, Wang Y, Yu X F, et al. Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: Molecular dynamics simulation and MM-GBSA calculation. Computational Biology and Chemistry 2020; 85: 107241. doi: 10.1016/j.compbiolchem.2020.107241
5. Jester BJ, Uyeki TM, Jernigan DB. Fifty years of influenza A(H3N2) following the pandemic of 1968. American Journal of Public Health 2020; 110(5): 669–676. doi: 10.2105/AJPH.2019.305557
6. York A, Fodor E. Biogenesis, assembly, and export of viral messenger ribonucleoproteins in the influenza A virus infected cell. RNA Biology 2013; 10(8): 1274–1282. doi: 10.4161/rna.25356
7. Massari S, Goracci L, Desantis J, Tabarrini O. Polymerase acidic protein–basic protein 1 (PA–PB1) protein–protein interaction as a target for next-generation anti-influenza therapeutics. Journal of Medicinal Chemistry 2016; 59(17): 7699–7718. doi: 10.1021/acs.jmedchem.5b01474
8. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. The Journal of Infectious Diseases 2007; 196(2): 249–257. doi: 10.1086/518936
9. Hussain M, Galvin HD, Haw TY, et al. Drug resistance in influenza A virus: The epidemiology and management. Infection and Drug Resistance 2017; 10: 121–134. doi: 10.2147/IDR.S105473
10. Poole EL, Medcalf L, Elton D, Digard P. Evidence that the C-terminal PB2-binding region of the influenza A virus PB1 protein is a discrete α-helical domain. FEBS Letters 2007; 581(27): 5300–5306. doi: 10.1016/j.febslet.2007.10.025
11. Selamoglu Z. Polyphenolic compounds in human health with pharmacological properties. Journal of Traditional Medicine & Clinical Naturopathy 2017; 6(4): e137.
12. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981−2002. Journal of Natural Products 2003; 66(7): 1022–1037. doi: 10.1021/np030096l
13. Fine DH, Furgang D, Barnett ML, et al. Effect of an essential oilcontaining antiseptic mouthrinse on plaque and salivary Streptococcus mutans levels. Journal of Clinical Periodontology 2000; 27(3): 157–161. doi: 10.1034/j.1600-051x.2000.027003157.x
14. Kareem SO, Akpan I, Ojo OP. Antimicrobial activities of Calotropis procera on selected pathogenic microorganisms. African Journal of Biomedical Research 2008; 11(1). doi: 10.4314/ajbr.v11i1.50674
15. Aliyu RM, Abubakar MB, Kasarawa AB, et al. Efficacy and phytochemical analysis of latex of Calotropis procera against selected dermatophytes. Journal of Intercultural Ethnopharmacology 2015; 4(4): 314–317. doi: 10.5455/jice.20151012012909
16. Wadhwani BD, Mali D, Vyas P, et al. A review on phytochemical constituents and pharmacological potential of Calotropis procera. RSC Advances 2021; 11: 35854–35878. doi: 10.1039/D1RA06703F
17. Iqbal J, Mishra RP, Allie AH. Antidermatophytic activity of angiospermic plants: A review. Asian Journal of Pharmaceutical and Clinical Research 2015; 8(2): 75–80.
18. Dirir AM, Cheruth AJ, Ksiksi TS. Ethnomedicine, phytochemistry and pharmacology of Calotropis procera and Tribulus terrestris. Journal of Natural Remedies 2017; 17(2): 38–47. doi: 10.18311/jnr/2017/11043
19. Sharma M, Tandon S, Nayak UA, et al. Calotropis gigantea extract as a potential anticariogenic agents against Streptococcus mutans: An in vivo comparative evaluation. Journal of Conservative Dentistry 2017; 20(3): 174–179. doi: 10.4103/JCD.JCD_13_16
20. Ishnava KB, Chauhan JB, Garg AA, Thakkar AM. Antibacterial and phytochemical studies on Calotropis gigantia (L.) R. Br. latex against selected cariogenic bacteria. Saudi Journal of Biological Sciences 2012; 19(1): 87–91. doi: 10.1016/j.sjbs.2011.10.002
21. Sehgal R, Arya S, Kumar VL. Inhibitory effect of extracts of latex of Calotropis procera against Candida albicans: A preliminary study. Indian Journal of Pharmacology 2005; 37(5): 334–335.
22. Barcellos MP, Santos CBR, Federico LB, et al. Pharmacophore and structure-based drug design, molecular dynamics and admet/tox studies to design novel potential pad4 inhibitors. Journal of Biomolecular Structure and Dynamics 2019; 37(4): 966–981. doi: 10.1080/07391102.2018.1444511
23. Reich S, Guilligay D, Pflug A, et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 2014; 516: 361–366. doi: 10.1038/nature14009
24. Venkataraman S, Prasad BVLS, Selvarajan R. RNA dependent RNA polymerases: Insights from structure, function and evolution. Viruses 2018; 10(2): 76. doi: 10.3390/v10020076
25. Liu Z, Zhao J, Li W, et al. Computational screen and experimental validation of anti-influenza effects of quercetin and chlorogenic acid from traditional Chinese medicine. Scientific Reports 2016; 6: 19095. doi: 10.1038/srep19095
26. Lima SL, Colombo AL, de Almeida Junior JN. Fungal cell wall: Emerging antifungals and drug resistance. Frontiers in Microbiology 2019; 10: 2573. doi: 10.3389/fmicb.2019.02573
DOI: https://doi.org/10.24294/th.v6i2.2940
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This site is licensed under a Creative Commons Attribution 4.0 International License.